Lead Product(s) : AP402
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AP Biosciences Doses First HER2+ Cancer Patient in AP402 Trial
Details : AP402, a potential first-in-class, next generation T cell engager targeting CD137 and p95HER2 in patients relapsed/refractory to anti-HER2 treatment.
Product Name : AP402
Product Type : Antibody
Upfront Cash : Inapplicable
April 22, 2025
Lead Product(s) : AP402
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Silmitasertib,Irinotecan Hydrochloride,Temozolomide
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Grants RPD Designation to Senhwa Bio’ Silmitasertib for Pediatric Neuroblastoma
Details : CX-4945 (silmitasertib) is a first-in-class small molecule drug that acts as a CK2 inhibitor. It is being evaluated for the treatment of pediatric neuroblastoma.
Product Name : CX-4945
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 09, 2024
Lead Product(s) : Silmitasertib,Irinotecan Hydrochloride,Temozolomide
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OBI-992
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
OBI Pharma Initiates Phase 1/2 Study for OBI-992, a TROP2-Targeted ADC
Details : OBI-992 is a novel antibody drug conjugate (ADC) cancer therapy targeting TROP2. It is being evaluated for the treatment of non-small cell lung cancer, small cell lung cancer & gastric cancer.
Product Name : OBI-992
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
December 06, 2024
Lead Product(s) : OBI-992
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Granaticin B,Azacitidine,Venetoclax
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lin BioScience Receives U.S. FDA Fast Track Designation for LBS-007
Details : LBS-007 is a natural, non-ATP cell cycle inhibitor targeting a broad array of cancers. It is being evaluated for the treatment of patients with relapsed or resistant acute leukaemias.
Product Name : LBS-007
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 27, 2024
Lead Product(s) : Granaticin B,Azacitidine,Venetoclax
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ABT-101
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : CDIB
Deal Size : $12.5 million
Deal Type : Series A Financing
Anbogen Secures $12.5M in Series A Funding for Precision Oncology Drug Development
Details : The financing aims to support the ongoing development of Anbogen's lead candidate ABT-101, a HER2-targeting TKI. It is being evaluated in non-small cell lung cancer and other advanced solid tumors.
Product Name : ABT-101
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 31, 2024
Lead Product(s) : ABT-101
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : CDIB
Deal Size : $12.5 million
Deal Type : Series A Financing
Lead Product(s) : Antroquinonol,Gemcitabine,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Hocena (antroquinonol) inhibits Ras and Ras-related GTP-binding protein activation and is being investigated in combination with the standard of care nab-paclitaxel plus gemcitabine for first-line treatment of metastatic pancreatic cancer.
Product Name : Hocena
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
May 05, 2023
Lead Product(s) : Antroquinonol,Gemcitabine,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ABT-101
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : National Health Research Institutes
Deal Size : Inapplicable
Deal Type : Inapplicable
AnBogen Therapeutics Receives Approval from U.S. FDA for Phase Ib/II Protocol Amendment for ABT-101
Details : ABT-101 (DBPR112) demonstrates excellent therapeutic potential and superior safety profile compared to competitors that are under clinical development. It meets challenges of unmet medical needs for cancer drugs targeting exon 20 insertions in HER2.
Product Name : ABT-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 13, 2022
Lead Product(s) : ABT-101
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : National Health Research Institutes
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OBI-999
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : OBI-999, uses Globo H antibody to recognize the cancer cells with high Globo H expression and releases the active drug to prevent tumor growth and kill tumor cells.
Product Name : OBI-999
Product Type : Antibody
Upfront Cash : Inapplicable
May 17, 2022
Lead Product(s) : OBI-999
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OBI-888
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : A first in class monoclonal antibody cancer immunotherapy, OBI-888 targets Globo H, antibody, a glycolipid antigen expressed in up to 15 epithelial cancers.
Product Name : OBI-888
Product Type : Antibody
Upfront Cash : Inapplicable
May 07, 2022
Lead Product(s) : OBI-888
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Silmitasertib,Cisplatin,Gemcitabine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : USFDA has granted Orphan drug designation for CX-4945 (silmitasertib), a highly selective inhibitor of casein kinase 2, on the basis of significant results from pre-clinical studies which demonstrate DNA repair and induce apoptosis in patients with Bilia...
Product Name : CX-4945
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 20, 2022
Lead Product(s) : Silmitasertib,Cisplatin,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable